Skip to content

Targeted Temperature Management After In-Hospital Cardiac Arrest

Targeted Temperature Management at 36℃ After In-Hospital Cardiac Arrest Trial(TTM36-IHCA Trial): An Investigator-Initiated, Single-Center, Randomized, Controlled, Assessor-Blinded, Pilot Clinical Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02578823
Acronym
TTM36-IHCA
Enrollment
60
Registered
2015-10-19
Start date
2016-01-31
Completion date
2018-04-30
Last updated
2016-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypoxic Ischemic Encephalopathy

Keywords

Targeted Temperature Management(TTM), in-hospital cardiac arrest(IHCA), restoration of spontaneous circulation(ROSC), unconsciousness, brain injury

Brief summary

The purpose of this study is to determine whether targeted temperature management at 36.0˚C(TTM-36) in patients who remain unconscious after resuscitation from in-hospital cardiac arrest(IHCA) will reduce death and disability compared with fever control. For this purpose, the current pilot study will be undertaken to establish the feasibility, safety, and surrogate outcomes of hypoxic-ischemic brain injury in 60 patients who remain unconscious after resuscitation from IHCA. Eligible patients will be randomly assigned in a 2:1 ratio to either TTM-36(n=40) or conventional treatment group(n=20). Randomization will be performed with stratification according to initial rhythm (shockable vs. non-shockable).

Interventions

DEVICEArctic Sun®

Core temperature is maintained to 36℃ for 3 days by using the skin attached pad(Arcticgel™) and targeted temperature management(Arctic Sun®).

DEVICEArcticgel™
PROCEDUREConventional antipyretic treatment

Conventional antipyretic treatment for fever includes using of antipyretics, ice packs, circulating fan, and tepid bathing, etc.

Sponsors

Asan Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Age 18-80 years * In-hospital cardiac arrest requiring chest compression for \> 2 minutes * Sustained restoration of spontaneous circulation(ROSC) for \> 20 minutes after cardiopulmonary resuscitation(CPR) * Unresponsive state(lack of meaningful response to verbal commands) for \> 20 minutes after sustained ROSC * Informed consents from a patient's family member

Exclusion criteria

* Unavailable TTM within 2 hours after ROSC * CPR duration \> 30 minutes * Unwitnessed arrest with initial rhythm asystole * Under or planned for extracorporeal membrane oxygenation(ECMO) * Initial body temperature \< 33 °C * Preexisting terminal illness with life expectancy \<6 months * Pre-admission CPC score of 3-5 * Pre-admission mRS score 4-6 * Unresponsive(stupor or coma) before cardiac arrest * Suspected or confirmed cause of cardiac arrest is diseases of the central nervous system, such as stroke, brain tumor, or amyotrophic lateral sclerosis * Any condition in which direct skin surface cooling would be contraindicated, such as large burns, unhealed surgical wounds, decubitus ulcers, cellulitis, or other conditions with disrupted skin integrity * Active massive bleeding * Major surgery within last 48 hours * Cardiothoracic surgery within 14 days * Planned surgery within next 72 hours after ROSC * Enrolled in other clinical trials * Pregnant women * Do-not-resuscitate(DNR) state * Patients whose family or treating physicians refuse to join this study

Design outcomes

Primary

MeasureTime frameDescription
Combination of death and poor neurological function defined as a Cerebral Performance Category (CPC) score 3 to 5 at 180 daysday 180Efficacy of targeted temperature management at 36.0℃(TTM-36) will be assessed by using Cerebral Performance Category(CPC) score. CPC score is the surrogate outcome for hypoxic-ischemic brain injury.

Secondary

MeasureTime frameDescription
Myoclonic or tonic-clonic seizures or status epilepticus(SE)up to day 7
The CPC score 3 to 5 at day 7 and at day 30day 7, day 30
The highest levels of serum neuron specific enolase(NSE) during the first 5 daysup to day 5
Unfavorable Electroencephalography(EEG) patternsday 0, day 4* Generalized suppression(≤20 μV) * Burst-suppression with generalized epileptiform activity * Generalized periodic epileptiform discharges on a flat background * No EEG reactivity * Electrographical seizures * Electrographical status epilepticus
Assessment of magnetic resonance imaging(MRI) at day 4day 4* Total magnetic resonance imaging(MRI) scores * The percentage of brain volume with Afferent Diffusion Coefficient(ADC) values \< 650 x 10\^-6mm\^2/sec * The percentage of brain volume with ADC values \< 450 x 10\^-6mm\^2/sec * Number of cerebral microbleeds
Other neurological evaluationsday 180* Depression: BDI (Beck Depression Inventory) * Quality of life: SF-36 (Short-Form 36-item Health Survey) * Activities of daily life: S-IADL (Seoul-Instrumental Activities of Daily Living) * Psychiatric symptoms: NPI (Neuropsychiatric Inventory) * Cognition: IQCODE (Informant Questionnaire on Cognitive Decline in the Elderly) * Parkinsonism: UPDRS (Unified Parkinson's Disease Rating Scale) * Ataxia: ICARS (International Cooperative Ataxia Rating Scale)
Assessment of follow-up MRIday 30 & day 180* Resting state functional MRI: Connectivity strength, proportional increase of connectivity strength on resting state * Diffusion tensor imaging: Global mean diffusivity, gray matter mean diffusivity, white matter mean diffusivity , mean fractional anisotropy, proportional increase of white matter global fractional anisotropy, proportional increase of white matter global mean diffusivity * High resolution T1-weighted imaging for MRI volumetric: Mean volume of the brain, mean volume of the gray matter of the brain, mean volume of the white matter of the brain, proportional increase of mean volume of the brain, proportional increase of mean volume of the gray matter, proportional increase of mean volume of the white matter * Susceptibility-weighted imaging: Number of cerebral microbleeds
Modified Rankin Scale(mRS) score 4 to 6 at day 30 and at Day 180day 30, day 180
All-cause mortality at day 30, at Day 180up to day 180
Neurological status estimated by the Seoul Neurosychological Screeninig Battery (SNSB) 2nd ed.day 180* Attention: Digit span (forward), digit span (backward) * Language & related function: Spontaneous speech, comprehension, repetition, reading, writing, finger naming, body part identification, right-left orientation, calculation; BNT (Boston Naming Test) * Visuospatial: RCFT (Rey Complex Figure Test) copy score * Memory: SVLT (Seoul Verbal Learning Test), RCFT (immediate recall, delayed recall, recognition) * Frontal & executive function: COWAT (Controlled Oral Word Association Test), CWST (Color Word Stroop Test), DSC (Digit Symbol Coding), TMT (Trail making test) * General cognitive index: MMSE (Mini Mental State Examination), CDR (Clinical Dementia Rating), GDS (Global Deterioration Scale) * Activities of daily living (ADL): Barthel index

Other

MeasureTime frameDescription
Safety of the targeted temperature management at 36.0℃(TTM-36)up to day 7Safety will be assessed by the composite measurement below everyday during the first 7 days after cardiac arrest. * Cardiac arrest after randomization * Arrhythmia(ventricular fibrillation, ventricular tachycardia, atrial fibrillation, atrial flutter, tachycardia \>130/min lasting more than 1 hour, and bradycardia \<40/min lasting more than 1 hour) * Pneumonia(pulmonary infiltration on the chest radiography and 2 or more of fever, leukocytosis, and purulent tracheobronchial secretions) * Septic shock(sepsis-induced hypotension persisting despite adequate fluid resuscitation) * Culture-proven infection * Major bleeding(bleeding requiring more than 2 units of packed red blood cell over 2 hours, bleeding causing fatality, and symptomatic bleeding in critical organs) * Shivering(the Bedside Shivering Assessment Scale 2-3)
Feasibilityup to day 180* 2.5 subjects per month can be recruited * At least 50% of all eligible patients can be recruited * No more than 10% of all recruited subjects cross over from one modality to the other * Complete follow-up in at least 90% of all recruited subjects

Countries

South Korea

Contacts

Primary ContactSang-Beom Jeon, Dr
sbjeonmd@gmail.com82-2-3010-3440

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026